Home
Products
Learn
About
Pricing
Log In
FRI
Asset Logo

Finbar Group Limited

๐Ÿ‡ฆ๐Ÿ‡บ ASX

Compare
Add to watchlist
๐Ÿ‘‘ Overview

๐Ÿ“ˆ Performance

๐Ÿ’ฐ Dividends

๐Ÿ’ต Cost

๐Ÿค“ Advanced

๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘งโ€๐Ÿ‘ฆ Community

๐Ÿ“ˆ

N/A
Annual Growth

5 years average annual capital growth

๐Ÿ’ฐ

5.73%
Annual dividend yield

Based on the most recent dividend

๐Ÿ’ต

$ 500
Minimum Order

Due to regulatory requirements

๐ŸŒ

0
Pearlers Invested

Since January 2020

๐Ÿ‘‘ Overview

Key information
๐Ÿ”Ž Fund Overview

Finbar Group Ltd. engages in the development of medium to high density residential apartments and commercial property. The company is headquartered in Perth, Western Australia and currently employs 28 full-time employees. The firm is focused on the development of medium to high-density residential buildings and commercial developments in Western Australia by way of direct ownership, ownership through fully owned subsidiaries or by equity accounted investees. Its segments include Residential Apartment Development, Commercial Office/Retail development, and Rental of Property. Its segments are all located in West Australia. The firm's projects include The Point Springs Residences, AT238, Civic Heart, Aurora Applecross, Dianella Apartments, One Kennedy and Sabina Applecross. The firm holds its rental properties through 175 Adelaide Terrace Pty Ltd, 31 Rowe Avenue Pty Ltd, 32 Riversdale Road Pty Ltd, 36 Chester Avenue Pty Ltd, 43 McGregor Road Pty Ltd, 5-7 Harper Terrace Pty Ltd, Finbar Karratha Pty Ltd and Finbar Commercial Pty Ltd.

๐Ÿ“ˆ Performance

Price History

-26.70%

1M

10Y

Graph

Table

Unsure how much or often to invest?
๐Ÿ—“๏ธ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out โ†’
๐Ÿ’ต Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out โ†’
โฑ๏ธ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out โ†’

๐Ÿ’ฐ Dividends

Payouts

๐Ÿ’ฐ Annual Dividend Yield*

5.73%

๐Ÿ’ฐ Annual Dividend Earnings Per $1,000 invested**

$57.35

๐Ÿ’ฐ Most Recent Dividend Franked Percentage Estimate

100.00%

๐Ÿ’ฐ Average Dividend Franked Percentage Estimate

100.00 %

๐Ÿ’ฐ Dividend reinvestment

Learn more

* Based on the most recent dividend

** Calculated by multiplying the most recent dividend yield by $1,000

Dividend History

1Y

5Y

10Y

Graph

Table

Year
Yearly Dividend Earnings Per Share
Franking Estimate

2025

$0.00

0.00%

2024

$0.00

0.00%

2023

$0.00

0.00%

2022

$0.04

100.00%

2021

$0.04

100.00%

2020

$0.03

100.00%

2019

$0.06

100.00%

2018

$0.06

100.00%

2017

$0.06

100.00%

2016

$0.07

100.00%

๐Ÿ’ต Costs

๐Ÿ’ต

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

๐Ÿ’ผ

N/A
Management Fee

Included in unit price, not charged by Pearler

๐Ÿ’ธ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐Ÿ’ธ Net fee calculator

๐Ÿค“ Advanced information

Technical Info

๐Ÿ’ฐ Price*

$0.65

*Price may be up to 24 hours old

๐Ÿ‘ฉโ€๐Ÿ‘ฉโ€๐Ÿ‘ฆ Community Insights

How our community is investing

๐ŸŒ Pearlers invested in FRI

0

๐Ÿ“Š Total Capital Earnings

N/A

๐Ÿ”ƒ Average investment frequency

N/A

๐Ÿ’ต Average investment amount

N/A

โฐ Last time a customer invested in FRI

692 days
FRI investor breakdown
๐Ÿ’ต Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

๐Ÿ‘ถ Age of investors

18 - 25

26 - 34

35 - 90

๐Ÿ™‹ Legal gender of investors

Female

Male

Pearlers who invest in FRI also invest in...

DHHF

DHHF.AX was created on 2019-12-03 by BetaShares. The fund's investment portfolio concentrates primarily on target outcome asset allocation. DHHF.AX aims to provide exposure to a low-cost, multi-asset class portfolio with high growth potential, for investors with a high tolerance for risk. DHHF.AX targets an allocation of 90% growth assets (shares and listed property), 10% defensive assets (bonds and cash).

๐Ÿ“Š Share price

$29.19 AUD
Find Out More

Want more shares? Try these...

Farm Pride Foods Ltd. engages in the provision of consumer goods, which includes the production, processing, and selling of egg and egg related products such as egg white, egg yolk, scrambled egg, fried eggs, crepes. The company is headquartered in Melbourne, Victoria. The firm is engaged in the production, processing, manufacturing and sale of eggs and egg products. The firm grades, packs, markets and distributes eggs and egg products. The company offers everything from pre-prepared egg products and wholesale ingredients. The firm offers egg products, such as whole egg, egg white, egg yolk, scrambled eggs, peeled boiled eggs, fried eggs, omelets, and egg cartoons. The firm serves domestic retail, industrial and food service sectors. The firm supplies all commercial markets, including the airline, hotel and restaurant industries amongst others, with its range of egg products. The firm sources its fresh eggs from its own farms and local suppliers across the country. The company holds significant assets, including egg farms around the country. The company also operates processing and grading facilities.

๐Ÿ“Š Share price

$0.13 AUD

Firebrick Pharma Ltd. is a pharmaceutical company, which engages in the development and commercialization of nasal spray treatment for the common cold based around the potential of povidone-iodine as an antimicrobial agent. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The firm is engaged in developing and commercializing a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold and a second patent family covering the prevention of pandemic viral diseases, including COVID-19. The company also has a third patent family covering the Nasodine formulation. The company is completing two major clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals. Positive Phase 3 trial results also be important for securing regulatory approvals and partnerships in markets outside Australia.

๐Ÿ“Š Share price

$0.16 AUD
Compare
Add to watchlist